Abstract
To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initiated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prognostic factors. In this commentary, we discuss the importance and limits of patient registries to support decision-making in thoracic cancer during the SARS-CoV-2 pandemic.
| Original language | English |
|---|---|
| Pages (from-to) | 602-604 |
| Number of pages | 3 |
| Journal | Cancer Cell |
| Volume | 38 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 9 Nov 2020 |
Keywords
- CANCER
- COVID-19
- IMPACT
- WUHAN
Access to Document
- 10.1016/j.ccell.2020.10.002Licence: Free access - publisher
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Cancer Cell, Vol. 38, No. 5, 09.11.2020, p. 602-604.
Research output: Contribution to journal › Editorial › Academic › peer-review
TY - JOUR
T1 - Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment
T2 - The TERAVOLT Experience
AU - Trama, Annalisa
AU - Proto, Claudia
AU - Whisenant, Jennifer G.
AU - Torri, Valter
AU - Cortellini, Alessio
AU - Michielin, Olivier
AU - Barlesi, Fabrice
AU - Dingemans, Anne-Marie C.
AU - Van Meerbeeck, Jan
AU - Pancaldi, Vera
AU - Mazieres, Julien
AU - Soo, Ross A.
AU - Leighl, Natasha B.
AU - Peters, Solange
AU - Wakelee, Heather
AU - Horn, Leora
AU - Hellmann, Matthew
AU - Wong, Selina K.
AU - Garassino, Marina Chiara
AU - Baena, Javier
N1 - Funding Information: C.P. received personal fees from Roche, Lilly, and Bristol-Myers Squibb and grants and travel reimbursement from Merck Sharp & Dohme, Roche, and Bristol-Myers Squibb. A.C. received grant consultancies from BMS, MSD, Astrazeneca, and Roche and speaker’s fees from Astrazeneca, Astellas, and Novartis. O.M. has received grants and personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, and Amgen and personal fees from Novartis. A.-M.C.D. attended advisory boards and/or provided lectures for Roche, Eli Lilly, Boehringer Ingelheim, Astra Zeneca, Pfizer, BMS, Amgen, Novartis, MSD, Takeda, and Pharmamar, received research support from BMS , AbbVie , and Amgen . R.S. received honoraria from Amgen, Astra-Zeneca, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, and Yuhan and research funding from Astra-Zeneca and Boehringer Ingelheim. N.L. received honoraria (CME lectures) from BMS, Boehringer Ingelheim, and MSD. Institutional research funding has been received from Astra Zeneca, Amgen, Array, Bayer, EMD Serono, Lilly, Roche, Guardant Health, Pfizer, Takeda, MSD. S.P. received education grants, provided consultation, attended advisory boards, and/or provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution). H.W. reports honoraria for advisory board participation from AstraZeneca, Blueprint, Xcovery, Janssen, Daiichi Sankyo, Helsinn, and Mirati; publishing fees from UpToDate; and research support paid to institution from ACEA Biosciences, Arrys Therapeutics, AztraZeneca/MedImmune, BMS, Celgene, Clovis Oncology, Exelixis, Genetech/Roche, Lilly, Merck, Novartis, Pfizer, Pharmacyclics, and Xcovery outside the submitted work. L.H. has received grants, personal fees, and travel reimbursement from Xcovery; grants and travel reimbursement from Bristol Myers Squibb; grants from Boheringer/Ingelherim; and personal fees from AstraZeneca, Roche, Incyte, Merck, Pfizer, Xcovery, EMD, Tesaro, AbbVie, Medscape, Physicians Education Resource, Research to Practice, Onclive, Amgen, and Bayer. M.D.H. received research support from Bristol-Myers Squibb; has been a compensated consultant for Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Shattuck Labs, Immunai, Blueprint Medicines, Achilles, and Arcus; received travel support/honoraria from AstraZeneca, Eli Lilly, and Bristol-Myers Squibb; has options from Shattuck Labs, Immunai, and Arcus; and has a patent filed by his institution related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. M.C.G. received grants, personal fees, and other financial support from Merck Sharp & Dohme, AstraZeneca, Novartis, Roche, Pfizer, Celgene; grants and other financial support from Tiziana Sciences, Clovis, GlaxoSmithKline, Spectrum, and Blueprint; personal fees and other financial support from Eli Lilly and Bristol Myers Squibb; grants from Merck and Bayer; personal fees from Boheringer, Otsuka Pharma, Incyte, Inivata, Takeda, Bayer, Sanofi, Seattle Genetics, and Daichii Sankyo; and other financial support from Merck Serono. J.B. received support for advisory/consultancy from Astra Zeneca, honoraria (self), and travel and accommodation expenses from Angelini. Funding Information: IInternational Association for the Study of Lung Cancer (IASLC) provided funding. Conceptualization, A.T. M.C.G. C.P. and J.B.; Methodology, A.T. V.T. and C.P.; Writing – Original Draft, A.T. C.P. M.C.G. L.H. H.W. J.B. and S.P.; Writing – Review & Editing, A.T. C.P. J.G.W. V.T. A.C. O.M. F.B. A.C.D. J.V.M. V.P. J.M. R.A.S. N.B.L. S.P. H.W. L.H. M.H. S.K.W. M.C.G. and J.B. Supervision, M.C.G. L.H. S.P. J.B. and H.W. Project Administration, M.C.G. L.H. S.P. H.W. F.B. A.C.D. and J.V.M. C.P. received personal fees from Roche, Lilly, and Bristol-Myers Squibb and grants and travel reimbursement from Merck Sharp & Dohme, Roche, and Bristol-Myers Squibb. A.C. received grant consultancies from BMS, MSD, Astrazeneca, and Roche and speaker's fees from Astrazeneca, Astellas, and Novartis. O.M. has received grants and personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, and Amgen and personal fees from Novartis. A.-M.C.D. attended advisory boards and/or provided lectures for Roche, Eli Lilly, Boehringer Ingelheim, Astra Zeneca, Pfizer, BMS, Amgen, Novartis, MSD, Takeda, and Pharmamar, received research support from BMS, AbbVie, and Amgen. R.S. received honoraria from Amgen, Astra-Zeneca, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, and Yuhan and research funding from Astra-Zeneca and Boehringer Ingelheim. N.L. received honoraria (CME lectures) from BMS, Boehringer Ingelheim, and MSD. Institutional research funding has been received from Astra Zeneca, Amgen, Array, Bayer, EMD Serono, Lilly, Roche, Guardant Health, Pfizer, Takeda, MSD. S.P. received education grants, provided consultation, attended advisory boards, and/or provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution). H.W. reports honoraria for advisory board participation from AstraZeneca, Blueprint, Xcovery, Janssen, Daiichi Sankyo, Helsinn, and Mirati; publishing fees from UpToDate; and research support paid to institution from ACEA Biosciences, Arrys Therapeutics, AztraZeneca/MedImmune, BMS, Celgene, Clovis Oncology, Exelixis, Genetech/Roche, Lilly, Merck, Novartis, Pfizer, Pharmacyclics, and Xcovery outside the submitted work. L.H. has received grants, personal fees, and travel reimbursement from Xcovery; grants and travel reimbursement from Bristol Myers Squibb; grants from Boheringer/Ingelherim; and personal fees from AstraZeneca, Roche, Incyte, Merck, Pfizer, Xcovery, EMD, Tesaro, AbbVie, Medscape, Physicians Education Resource, Research to Practice, Onclive, Amgen, and Bayer. M.D.H. received research support from Bristol-Myers Squibb; has been a compensated consultant for Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Shattuck Labs, Immunai, Blueprint Medicines, Achilles, and Arcus; received travel support/honoraria from AstraZeneca, Eli Lilly, and Bristol-Myers Squibb; has options from Shattuck Labs, Immunai, and Arcus; and has a patent filed by his institution related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. M.C.G. received grants, personal fees, and other financial support from Merck Sharp & Dohme, AstraZeneca, Novartis, Roche, Pfizer, Celgene; grants and other financial support from Tiziana Sciences, Clovis, GlaxoSmithKline, Spectrum, and Blueprint; personal fees and other financial support from Eli Lilly and Bristol Myers Squibb; grants from Merck and Bayer; personal fees from Boheringer, Otsuka Pharma, Incyte, Inivata, Takeda, Bayer, Sanofi, Seattle Genetics, and Daichii Sankyo; and other financial support from Merck Serono. J.B. received support for advisory/consultancy from Astra Zeneca, honoraria (self), and travel and accommodation expenses from Angelini. Publisher Copyright: © 2020 Elsevier Inc.
PY - 2020/11/9
Y1 - 2020/11/9
N2 - To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initiated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prognostic factors. In this commentary, we discuss the importance and limits of patient registries to support decision-making in thoracic cancer during the SARS-CoV-2 pandemic.
AB - To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initiated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prognostic factors. In this commentary, we discuss the importance and limits of patient registries to support decision-making in thoracic cancer during the SARS-CoV-2 pandemic.
KW - CANCER
KW - COVID-19
KW - IMPACT
KW - WUHAN
U2 - 10.1016/j.ccell.2020.10.002
DO - 10.1016/j.ccell.2020.10.002
M3 - Editorial
C2 - 33091381
SN - 1535-6108
VL - 38
SP - 602
EP - 604
JO - Cancer Cell
JF - Cancer Cell
IS - 5
ER -